Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention

References

• Jackson AC, editor. Rabies. 3rd ed. New York (NY): Academic Press; 2013.
   Google Scholar
• Rupprecht CE, Plotkin SA. Rabies vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Elsevier Saunders; 2013. p. 636–668.
   Google Scholar
• Kuzmin IV. Basic facts about lyssaviruses. In: Rupprecht CE, Nagarajan T, Eds. Current laboratory techniques in rabies: diagnosis, research and prevention. Vol. 1. New York (NY): Academic Press; 2014. p. 3–21.
   Google Scholar
• Kuzmin IV, Rupprecht CE. Bat lyssaviruses. In: Wang LF, Cowled C, editors. Bats and viruses. Hoboken (NJ): John Wiley & Sons; 2015. p. 47–97.
   Google Scholar
• Taylor LH, Knopf L, the Partners for Rabies Prevention. Surveillance of human rabies by national authorities - a global survey. Zoonoses Public Health. 2015;62(7):543–552.
   PubMed Web of Science ®Google Scholar
• Hampson K, Coudeville L, Lembo T, et al. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015;9:e0003709.
   PubMed Web of Science ®Google Scholar
• Willoughby RE Jr. Rabies: rare human infection - common questions. Infect Dis Clin North Am. 2015;29(4):637–650.
   PubMed Web of Science ®Google Scholar
• Lankester F, Hampson K, Lembo T, et al. Infectious disease. Implementing Pasteur’s vision for rabies elimination. Science. 2014;345:1562–1564.
   PubMed Web of Science ®Google Scholar
• Lembo T. Partners for rabies prevention. The blueprint for rabies prevention and control: a novel operational toolkit for rabies elimination.Plos Negl Tropdis. 2012;6:e1388.
   PubMed Web of Science ®Google Scholar
• Abbas SS, Kakkar M. Rabies control in India: a need to close the gap between research and policy. Bull World Health Organ. 2015;93:131–132.
   PubMed Web of Science ®Google Scholar
• Yao HW, Yang Y, Liu K, et al. The spatiotemporal expansion of human rabies and its probable explanation in mainland China, 2004-2013. PLoS Negl Trop Dis. 2015;9:e0003502.
   Web of Science ®Google Scholar
• Tarantola A, Ly S, In S, et al. Rabies vaccine and rabies immunoglobulin in Cambodia: use and obstacles to use. J Travel Med. 2015;22:348–352.
   PubMed Web of Science ®Google Scholar
• Vora NM, Orciari LA, Niezgoda M, et al. Clinical management and humoral immune responses to rabies post-exposure prophylaxis among three patients who received solid organs from a donor with rabies. Transpl Infect Dis. 2015;17:389–395.
   PubMed Web of Science ®Google Scholar
• Warrell MJ, Warrell DA. Rabies: the clinical features, management and prevention of the classic zoonosis. Clin Med. 2015;15:78–81.
   PubMed Web of Science ®Google Scholar
• Dodet B, Tejiokem MC, Aguemon AR, et al. Human rabies deaths in Africa: breaking the cycle of indifference. Int Health. 2015;7:4–6.
   PubMed Web of Science ®Google Scholar
• Wilde H, Hemachudha T, Wacharapluesadee S, et al. Rabies in Asia: the classical zoonosis. Curr Top Microbiol Immunol. 2013;365:185–203.
   PubMed Web of Science ®Google Scholar
• Feder HM Jr, Petersen BW, Robertson KL, et al. Rabies: still a uniformly fatal disease? Historical occurrence, epidemiological trends, and paradigm shifts. Curr Infect Dis Rep. 2012;14:408–422.
   PubMed Web of Science ®Google Scholar
• Baby J, Mani RS, Abraham SS, et al. Natural rabies infection in a domestic fowl (Gallus domesticus): a report from India. PLoS Negl Trop Dis. 2015;9:e0003942.
   PubMed Web of Science ®Google Scholar
• Rupprecht CE, Turmelle A, Kuzmin IV. A perspective on lyssavirus emergence and perpetuation. Curr Opin Virol. 2011;1:662–670.
   PubMed Web of Science ®Google Scholar
• Francis JR, McCall BJ, Hutchinson P, et al. Australian bat lyssavirus: implications for public health. Med J Aust. 2014;201:647–649.
   PubMed Web of Science ®Google Scholar
• Klevar S, Høgåsen HR, Davidson RK, et al. Cross-border transport of rescue dogs may spread rabies in Europe. Vet Rec. 2015;176:672.
   PubMed Web of Science ®Google Scholar
• Huang AS, Chen WC, Huang WT, et al. Public health responses to reemergence of animal rabies, Taiwan, July 16-December 28, 2013. PLoS One. 2015;10:e0132160.
   Google Scholar
• Widyastuti MD, Bardosh KL, Sunandar, et al. On dogs, people, and a rabies epidemic: results from a sociocultural study in Bali, Indonesia. Infect Dis Poverty. 2015;4:30.
   PubMed Web of Science ®Google Scholar
• Sinclair JR, Washburn F, Fox S, et al. Dogs entering the United States from rabies-endemic countries, 2011-2012. Zoon Publ Hlth. 2015;62:393–400.
   PubMed Web of Science ®Google Scholar
• Gluska S, Finke S, Perlson E. Receptor-mediated increase in rabies virus axonal transport. Neural Regen Res. 2015;10:883–884.
   PubMed Web of Science ®Google Scholar
• Blondel D, Maarifi G, Nisole S, et al. Resistance to Rhabdoviridae infection and subversion of antiviral responses. Viruses. 2015;7:3675–3702.
   PubMed Web of Science ®Google Scholar
• Bauer A, Nolden T, Nemitz S, et al. A dynein light chain 1 binding motif in rabies virus polymerase L protein plays a role in microtubule reorganization and viral primary transcription. J Virol. 2015;89:9591–9600.
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Li J, Faber M, et al. Concepts in the pathogenesis of rabies. Future Virol. 2008;3:481–490.
   PubMed Web of Science ®Google Scholar
• Masatani T, Ito N, Ito Y, et al. Importance of rabies virus nucleoprotein in viral evasion of interferon response in the brain. Microbiol Immunol. 2013;57:511–517.
   PubMed Web of Science ®Google Scholar
• Delmas O, Assenberg R, Grimes JM, et al. The structure of the nucleoprotein binding domain of lyssavirus phosphoprotein reveals a structural relationship between the N-RNA binding domains of Rhabdoviridae and Paramyxoviridae. RNA Biol. 2010;7:322–327.
   PubMed Web of Science ®Google Scholar
• Fouquet B, Nikolic J, Larrous F, et al. Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P. J Virol. 2015;89:1640–1651.
   PubMed Web of Science ®Google Scholar
• Pollin R, Granzow H, Köllner B, et al. Membrane and inclusion body targeting of lyssavirus matrix proteins. Cell Microbiol. 2013;15:200–212.
   PubMed Web of Science ®Google Scholar
• Guichard P, Krell T, Chevalier M, et al. Three dimensional morphology of rabies virus studied by cryo-electron tomography. J Struct Biol. 2011;176:32–40.
   PubMed Web of Science ®Google Scholar
• Genz B, Nolden T, Negatsch A, et al. Chimeric rabies viruses for trans-species comparison of lyssavirus glycoprotein ectodomain functions in virus replication and pathogenesis. Berl Munch Tierarztl Wochenschr. 2012;125:219–227.
   PubMed Web of Science ®Google Scholar
• Pulmanausahakul R, Li J, Schnell MJ, et al. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J Virol. 2008;82:2330–2338.
   PubMed Web of Science ®Google Scholar
• Chopy D, Pothlichet J, Lafage M, et al. Ambivalent role of the innate immune response in rabies virus pathogenesis. J Virol. 2011;85:6657–6668.
   PubMed Web of Science ®Google Scholar
• Zhao P, Zhao L, Zhang T, et al. Innate immune response gene expression profiles in central nervous system of mice infected with rabies virus. Comp Immunol Microbiol Infect Dis. 2011;34:503–512.
   PubMed Web of Science ®Google Scholar
• Li J, Faber M, Dietzschold B, et al. The role of toll-like receptors in the induction of immune responses during rabies virus infection. Adv Virus Res. 2011;79:115–126.
   PubMed Web of Science ®Google Scholar
• Srithayakumar V, Sribalachandran H, Rosatte R, et al. Innate immune responses in raccoons after raccoon rabies virus infection. J Gen Virol. 2014;95:16–25.
   PubMed Web of Science ®Google Scholar
• Solomon T, Marston D, Mallewa M, et al. Paralytic rabies after a two week holiday in India. BMJ. 2005;331:501–503.
   PubMed Web of Science ®Google Scholar
• Nathwani D, McIntyre PG, White K, et al. Fatal human rabies caused by European bat Lyssavirus type 2a infection in Scotland. Clin Infect Dis. 2003;37:598–601.
   PubMed Web of Science ®Google Scholar
• Cardenas Palomo LF 1, De Souza Matos DC, Chaves Leal E, et al. Lymphocyte subsets and cell proliferation analysis in rabies-infected mice. J Clin Lab Immunol. 1995;46:49–61.
   PubMedGoogle Scholar
• Thoulouze MI, Lafage M, Montano-Hirose JA, et al. Rabies virus infects mouse and human lymphocytes and induces apoptosis. J Virol. 1997;71:7372–7380.
   PubMed Web of Science ®Google Scholar
• Vidy A, Chelbi-Alix M, Blondel D. Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol. 2005;79:14411–14420.
   PubMed Web of Science ®Google Scholar
• Blaney JE, Marzi A, Willet M, et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 2013;9:e1003389.
   PubMed Web of Science ®Google Scholar
• Celis E, Miller RW, Wiktor TJ, et al. Isolation and characterization of human T cell lines and clones reactive to rabies virus: antigen specificity and production of interferon-gamma. J Immunol. 1986;136:692–697.
   PubMed Web of Science ®Google Scholar
• Ghaffari G, Passalacqua DJ, Bender BS, et al. Human lymphocyte proliferation responses following primary immunization with rabies vaccine as neoantigen. Clin Diagn Lab Immunol. 2001;8:880–883.
   PubMedGoogle Scholar
• Dorfmeier CL, Lytle AG, Dunkel AL, et al. Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection. J Virol. 2012;86:11533–11540.
   PubMed Web of Science ®Google Scholar
• Good-Jacobson KL, Shlomchik MJ. Plasticity and heterogeneity in the generation of memory B cells and long-lived plasma cells: the influence of germinal center interactions and dynamics. J Immunol. 2010;185:3117–3125.
   PubMed Web of Science ®Google Scholar
• Strady C, Andreoletti L, Baumard S, et al. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Trans R Soc Trop Med Hyg. 2009;103:1159–1164.
   PubMed Web of Science ®Google Scholar
• Strady A, Lang J, Lienard M, et al. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis. 1998;177:1290–1295.
   PubMed Web of Science ®Google Scholar
• Malerczyk C, Briggs DJ, Dreesen DW, et al. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med. 2007;14:63–64.
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Knowles BB, McCarrick JW, et al. Immune effector mechanisms required for protection to rabies virus. Virology. 1995;214:398–404.
   PubMed Web of Science ®Google Scholar
• Perry LL, Lodmell DL. Role of CD4+ and CD8+ T cells in murine resistance to street rabies virus. J Virol. 1991;65:3429–3434.
   PubMed Web of Science ®Google Scholar
• Tollis M, Dietzschold B, Volia CB, et al. Immunization of monkeys with rabies ribonucleoprotein (RNP) confers protective immunity against rabies. Vaccine. 1991;9:134–136.
   PubMed Web of Science ®Google Scholar
• Venkataswamy MM, Madhusudana SN, Sanyal SS, et al. Cellular immune response following pre-exposure and postexposure rabies vaccination by intradermal and intramuscular routes. Clin Exp Vaccine Res. 2015;4:68–74.
   PubMed Web of Science ®Google Scholar
• Carty M, Reinert L, Paludan SR, et al. Innate antiviral signaling in the central nervous system. Trends Immunol. 2014;35:79–87.
   PubMed Web of Science ®Google Scholar
• Luco S, Delmas O, Vidalain PO, et al. RelAp43, a member of the NF-κB family involved in innate immune response against Lyssavirus infection. PLoS Pathog. 2012;8:e1003060.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang H, Wu H, et al. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J Virol. 2011;85:1634–1644.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Expert consultation on rabies. Second report. WHO Tech Rep Ser. 2013;982:1–139.
   Web of Science ®Google Scholar
• Höper D, Freuling C, Müller T, et al. High definition viral vaccine strain identity and stability testing using full-genome population data - The next generation of vaccine quality control. Vaccine. 2015;33(43):5829–5837.
   PubMed Web of Science ®Google Scholar
• Finke S, Karger A, Freuling C, et al. Assessment of inactivated human rabies vaccines: biochemical characterization and genetic identification of virus strains. Vaccine. 2012;30:3603–3609.
   PubMed Web of Science ®Google Scholar
• Jordan I, Sandig V. Matrix and backstage: Cellular substrates for viral vaccines. Viruses. 2014;6:1672–1700.
   PubMed Web of Science ®Google Scholar
• Mahendra BJ, Madhusudana SN, Sampath G, et al. Immunogenicity, safety and tolerance of a purified duck embryo vaccine PDEV (VAXIRAB) for rabies post-exposure prophylaxis: results of a multicentric study in India. Hum Vacc. 2010;6:721–724.
   Web of Science ®Google Scholar
• Barrett PN, Mundt W, Kistner O, et al. Vero cell platform in vaccine production: moving towards cell-culture based viral vaccines. Exp Rev Vacc. 2009;8:607–618.
   PubMed Web of Science ®Google Scholar
• Uscher-Pines L, Barnett DJ, Sapsin JW, et al. A systematic analysis of influenza vaccine shortage policies. Publ Hlth. 2008;122:183–191.
   Web of Science ®Google Scholar
• Giesen A, Gniel D, Malerczyk C. 30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience. Exp Rev Vacc. 2015;14:351–367.
   PubMed Web of Science ®Google Scholar
• Ma B, He LF, Zhang YL, et al. Characteristics and viral propagation properties of a new diploid cell line, Walwax-2, and its suitability as a candidate cell substrate for vaccine production. Hum Vacc Immuno. 2015;11:998–1009.
   PubMed Web of Science ®Google Scholar
• Guo SH, Tao H, Ying ZF. Study on safety and immunogenicity of oral poliomyelitis attenuated live vaccine (human diploid cell). Zhongguo Yi Miao He Mian Yi. 2010;16:193–196.
   PubMedGoogle Scholar
• Toovey S. Preventing rabies with the Verorab vaccine: 1985-2005. Twenty years of clinical experience. Trav Med Infect Dis. 2007;5:327–348.
   PubMedGoogle Scholar
• World Health Organization. WHO pre-qualified vaccines: Geneva, last revised 2015. Available from: http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/.
   Google Scholar
• Rourou S, Ben Ayed Y, Trabelsi K, et al. An animal component free medium that promotes the growth of various animal cell lines for the production of viral vaccines. Vaccine. 2014;32:2767–2769.
   PubMed Web of Science ®Google Scholar
• Li R, Huang L, Li J, et al. A next-generation, serum-free, highly purified vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab when administered according to a post-exposure regimen in healthy children and adults in China. Vaccine. 2013;31:5940–5947.
   PubMed Web of Science ®Google Scholar
• Advisory Committee on Immunization Practices. Human rabies prevention. Mmwr. 2010;59(RR–2):1–9.
   PubMedGoogle Scholar
• Wieten RW, Leenstra T, Van Thiel PP, et al. Rabies vaccinations: are abbreviated intradermal schedules the future? Clin Infect Dis. 2013;56:414–419.
   PubMed Web of Science ®Google Scholar
• Savadogo M, Boushab MB. Rabies in children: an often unknown risk among populations at risk. Med Sante Trop. 2015;25:222–224.
   PubMedGoogle Scholar
• Wieten RW, Tawil S, Van Vugt M, et al. Risk of rabies exposure among travelers. Neth J Med. 2015;73:219–226.
   PubMed Web of Science ®Google Scholar
• Fooks AR, Koraka P, De Swart RL, et al. Development of a multivalent paediatric vaccine for rabies virus in combination with Measles-Mumps-Rubella (MMR). Vaccine. 2014;32:2020–2021.
   PubMed Web of Science ®Google Scholar
• Sadeghi M, Moallem SA, Yousefi-Abdolmaleki E, et al. The rabies early death phenomenon: A report of ineffective administration of rabies vaccine during symptomatic disease. Indian J Crit Care Med. 2015;19:422–424.
   PubMedGoogle Scholar
• Wilde H, Khawplod P, Hemachudha T, et al. Postexposure treatment of rabies infection: can it be done without immunoglobulin? Clin Infect Dis. 2002;34:477–480.
   PubMed Web of Science ®Google Scholar
• Froude JW, Stiles B, Pelat T, et al. Antibodies for biodefense. MAbs. 2011;3:517–527.
   PubMed Web of Science ®Google Scholar
• Bharti OK, Madhusudana SN, Gaunta PL, et al. Local infiltration of rabies immunoglobulins without systemic intramuscular administration: an alternative cost effective approach for passive immunization against rabies. Hum Vaccin Immunother. 2015. [ Epub ahead of print].
   PubMedGoogle Scholar
• Saylor C, Dadachova E, Casadevall A. Monoclonal antibody-based therapies for microbial diseases. Review Vaccine. 2009;27:G38–G46.
   Web of Science ®Google Scholar
• De Kruif J, Kramer A, Nijhuis R, et al. Generation of stable cell clones expressing mixtures of human antibodies. Biotechnol Bioeng. 2010;106:741–750.
   PubMed Web of Science ®Google Scholar
• Paul M, Van Dolleeweerd C, Drake PM, et al. Molecular pharming: future targets and aspirations. Hum Vaccin. 2011;7:375–382.
   PubMed Web of Science ®Google Scholar
• Bakker AB, Python C, Kissling CJ, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine. 2008;26:5922–5927.
   PubMed Web of Science ®Google Scholar
• Gogtay N, Thatte U, Kshirsagar N, et al. Safety and pharmacokinetics of a human monoclonal antibody to rabies virus: a randomized, dose-escalation phase 1 study in adults. Vaccine. 2012;30:7315–7320.
   PubMed Web of Science ®Google Scholar
• Van Dolleweerd CJ, Teh AY, Banyard AC, et al. Engineering, expression in transgenic plants and characterization of E559, a rabies virus-neutralizing monoclonal antibody. J Infect Dis. 2014;210:200–208.
   PubMed Web of Science ®Google Scholar
• Both L, Van Dolleweerd C, Wright E, et al. Production, characterization, antigenic specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. Faseb J. 2013;27:2055–2065.
   PubMed Web of Science ®Google Scholar
• Sun L, Chen Z, Yu L, et al. Generation and characterization of neutralizing human recombinant antibodies against antigenic site II of rabies virus glycoprotein. Appl Microbiol Biotechnol. 2012;96:357–366.
   PubMed Web of Science ®Google Scholar
• Turki I, Hammami A, Kharmachi H, et al. Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency. Mol Immunol. 2014;57:66–73.
   PubMed Web of Science ®Google Scholar
• Tinsa F, Borgi A, Jahouat I, et al. Rabies encephalitis in a child: a failure of rabies post exposure prophylaxis?. BMJ Case Rep. 2015.
   PubMedGoogle Scholar
• Ren J, Gong Z, Chen E, et al. Human rabies in Zhejiang Province, China. Int J Infect Dis. 2015;38:77–82.
   PubMed Web of Science ®Google Scholar
• Chung EH. Vaccine allergies. Clin Exp Vaccine Res. 2014;3:50–57.
   PubMedGoogle Scholar
• Gupta M, Sindher S, Saltzman R, et al. Evaluation and safe administration of rabies vaccine to a child presumably allergic to the gelatin content of the PCECV RabAvert. J Allergy Clin Immunol Pract. 2014;3:281–282.
   Web of Science ®Google Scholar
• Joob S. Rabies vaccination in special scenarios: A review. Adv Trop Med Publ Hlth Int. 2013;3:1–4.
   Google Scholar
• Malerczyk C, Freuling C, Gniel D, et al. Cross-neutralization of antibodies induced by vaccination with purified chick embryo cell vaccine (PCECV) against different lyssavirus species. Hum Vacc Immuno. 2014;10:2799–2804.
   PubMed Web of Science ®Google Scholar
• Evans JS, Horton DL, Easton AJ, et al. Rabies virus vaccines: Is there a need for a panlyssavirus vaccine? Vaccine. 2012;30:7447–7454.
   PubMed Web of Science ®Google Scholar
• Astray RM, Ventini DC, Boldorini VL, et al. Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors. Vaccine. 2014;32:2829–2832.
   PubMed Web of Science ®Google Scholar
• Wu Q, Yu F, Xu J, et al. Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model. Vet Microbiol. 2014;171:93–101.
   PubMed Web of Science ®Google Scholar
• Zhou D, Cun A, Li Y, et al. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther. 2006;14:662–672.
   PubMed Web of Science ®Google Scholar
• Gomme EA, Wanjalla CN, Wirblich C, et al. Rabies virus as a research tool and viral vaccine vector. Adv Virus Res. 2011;79:139–164.
   PubMed Web of Science ®Google Scholar
• Osinubi MO, Wu X, Franka R, et al. Enhancing comparative rabies DNA vaccine effectiveness through glycoprotein gene modifications. Vaccine. 2009;27:7214–7218.
   PubMed Web of Science ®Google Scholar
• Kumar BD, Kumar PU, Krishna TP, et al. Pre-clinical toxicity and immunobiological evaluation of DNA rabies vaccine and combination rabies vaccine in rhesus monkeys (Macaca mulatta). Indian J Med Res. 2013;137:1072–1088.
   PubMed Web of Science ®Google Scholar
• Cenna J, Hunter M, Tan GS, et al. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis. 2009;200:1251–1260.
   PubMed Web of Science ®Google Scholar
• Xiang ZQ, Greenberg L, Ertl HC, et al. Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology. 2014;450-451:243–249.
   PubMed Web of Science ®Google Scholar
• Hirao LA, Wu L, Khan AS, et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine. 2008;26:440–448.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1.
   PubMed Web of Science ®Google Scholar
• Ogwang C, Kimani D, Edwards NJ, et al. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med. 2015;7:286re5.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, et al. Chimpanzee adenovirus vector Ebola vaccine - preliminary report. N Engl J Med. 2014;373:776.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Fitzgerald JC, Reyes-Sandoval A, et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood. 2007;110:1916–1923.
   PubMed Web of Science ®Google Scholar
• Alcock R, Cottingham MG, Rollier CS, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med. 2010;2:19ra12.
   PubMed Web of Science ®Google Scholar
• Bahloul C, Ahmed SB, B’chir BI, et al. Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine. Vaccine. 2003;22:177–184.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen Z, Huang J, et al. Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection. J Virol. 2015;89:3427–3429.
   PubMed Web of Science ®Google Scholar
• Mahendra BJ, Narayana DA, Agarkhedkar S, et al. Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (PCECV) administered according to two different simulated post exposure intramuscular regimens (Zagreb versus Essen). Hum Vaccin Immunother. 2015;11:428–434.
   PubMed Web of Science ®Google Scholar
• Narayana A, Manoharan A, Narayan MS, et al. Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases. Hum Vaccin Immunother. 2015;11:1748–1753.
   PubMed Web of Science ®Google Scholar
• Qi Y, Kang H, Zheng X, et al. Incorporation of membrane-anchored flagellin or Escherichia coli heat-labile enterotoxin B subunit enhances the immunogenicity of rabies virus-like particles in mice and dogs. Front Microbiol. 2015;6:169.
   PubMed Web of Science ®Google Scholar